Related Experiment Videos
SCH 48973: a potent, broad-spectrum, antienterovirus compound
P J Buontempo1, S Cox, J Wright-Minogue
1Department of Antiviral Chemotherapy, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
Antimicrobial Agents and Chemotherapy
|June 1, 1997
Summary
SCH 48973 shows potent antiviral activity against enteroviruses, inhibiting viral replication and increasing survival in a mouse model. This novel molecule targets the viral capsid, offering a promising therapeutic candidate for enterovirus infections.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Enteroviruses are a significant cause of human illness.
- Existing antiviral therapies for enterovirus infections are limited.
- Novel therapeutic agents are needed to combat enterovirus diseases.
Purpose of the Study:
- To evaluate the antiviral activity and efficacy of SCH 48973 against enteroviruses.
- To investigate the mechanism of action of SCH 48973.
- To assess the therapeutic potential of SCH 48973 in a preclinical model.
Main Methods:
- In vitro assays measuring cytopathic effect inhibition and cytotoxicity.
- Testing against a panel of human enterovirus isolates.
- Viral capsid binding studies and kinetic analysis.
- In vivo efficacy studies in a murine model of poliovirus infection.
Main Results:
- SCH 48973 exhibited potent antiviral activity (IC50s: 0.02–0.11 µg/ml) against five picornaviruses with no cytotoxicity.
- It inhibited 80% of 154 human enterovirus isolates at an IC50 of 0.9 µg/ml.
- Binding studies confirmed interaction with the viral capsid (Ki: 8.85 x 10⁻⁸ M).
- Oral administration in mice increased survival and reduced viral titers in the brain.
Conclusions:
- SCH 48973 demonstrates potent in vitro and in vivo antienterovirus activity.
- Its specific interaction with the viral capsid underpins its efficacy.
- SCH 48973 is a promising candidate for therapeutic intervention against enterovirus infections.